Tag: nicotinic acid

Can you influence your biological age?

Claus Hancke

29 January 2024

The short answer is: “Yes. Of course you can.”
The difficult question is: “How much?”

It is not rocket science to figure out that you reduce your chances of a long and good life if you sit in solitude on the sofa all day, smoking, eating chips and drinking cola, sleeping too little and weighing too much. You age faster. It seems to be common knowledge.

Therefore, it is right up our street to start changing such habits if you want to increase the chance of a good and long life, i.e. slow down the speed at which you age. This is what is popularly called lowering one’s biological age.

This question is brought up to date by a popular Danish TV broadcast with mention of research done at the Danish state hospital, Rigshospitalet, where researchers are trying to influence the rate of aging so that you age more slowly or may become a little younger from a biological point of view.

And here they have also tackled the above-mentioned, specific bad habits, after which they “calculate” the biological age before, during and after the intervention.

So how do you calculate this biological age? It is, of course, a purely theoretical age, based on expected remaining life, calculated from an algorithm which is constructed according to the parameters that are now believed to affect life expectancy and the speed of aging in 2024.

The same persons may have a completely different biological age in 5 years, when science has exposed completely different parameters that affect life expectancy even more strongly. This particularly concerns various blood tests, i.e. biochemical parameters, where we are constantly getting smarter.

One of the most reliable measurements of a person’s biological age is probably the measurement of the remaining telomeres in the genetic material of the cell nuclei. These telomeres shorten during cell division, and when we have no more, we die. Many international researchers have been interested in this for the past 20 years, including the Swedish professor Urban Alehagen, who, as mentioned in a previous newsletter has researched the life-extending effect of Q10 and selenium.

In the above-mentioned TV broadcast, the various lifestyle measures have been supplemented by taking a pill with Nicotinamide Riboside, which supports the cells’ energy production.

Many have asked me what it is, and to bring clarity to the many abbreviations and biochemical contexts, I have made a small presentation which can be viewed on Youtube. It is difficult to describe these biochemical processes in a newsletter, which is why we supplement with this video.

Nicotiamide Riboside is only one of many forms of vitamin B3, all of which contribute to increased energy production in the cells’ power plants, where the cell makes its energy, the so-called mitochondria.

We consume vitamin B3 as nicotinic acid or nicotinamide, after which it is converted to nicotinamide riboside (NR) and then to nicotinamide mononucleoside (NMN), which is then converted to what it is all about, nicotinamide adenine dinucleotide (NAD) in the cells .

(NAD has the property that it can alternate between two oxidation stages NAD+ and NADH, thereby contributing to energy production together with Q10.) This takes place in the inner membrane of the mitochondria.

Whether you consume NR or NMN or Nicotinamide is a question of how far down the synthesis pathway you want to start. Overall, the end result will be roughly the same, just with a difference in the amount of NAD formed.

I apologize for the many abbreviations and the somewhat difficult explanation, which I hope my little video can make up for.

Supplements can be exciting and good, and even life-prolonging. But don’t forget the most important things:

A healthy diet, daily exercise, a good night’s sleep, avoid being overweight and stick with your friends from your youth. You won’t get new ones. Stop smoking and moderate your alcohol consumption. It all helps to raise your quality of life and slow down the aging process.

Take care of yourself and others.

Claus Hancke
Specialist in general medicine

The Vitality Council’s 7-minute video about NAD can be seen here:
https://youtu.be/66BTyE6c5UU
However, Danish is spoken and it is unfortunately not subtitled.

Vitamin B3, Research references

Admin

January 1999

1. Alhadeff L, Gualtieri GT, Lipton M. Toxic effects of water-soluble vitamins. Nutr Rev 42: 33-40, 1984.
2. Bendich A, Cohen M. Nutrition and immunology. New York: Alan R. Liss. p 114-115, 1988.
3. Carlson LA, Hamsten A, and Asplund A. Pronounced Lowering of Serum Levels of Lipoprotein Lp(a) in Hyperlipidaemic Subjects Treated with Nicotinic Acid, J Intern Med 226, 271-6, 1989.
4. Cheraskin E, Ringsdorf WM Jr, Medford FH. The ‘ideal’ daily niacin intake. Int J Vit Nutr Res 46: 58-60, 1976.
5. Cleary JP. Vitamin B3 in the Treatment of Diabetes Mellitus: Case Reports and Review of the Literature. J Nutr Med 1: 217-25, 1990.
6. DiPalma JR and Thayer WS, Use of Niacin as a Drug, Ann Rev Nutr 11; 169-87, 1991.
7. Einstein N, Baker A, Galper J et al. Jaundice due to nicotinic acid therapy. Am J Digest Dis 20: 282-286, 1975.
8. El-Enein AMA et al., The Role of Nicotinic Acid and Inositol Hexaniacinate as Anticholesterolemic and Antilipemic Agents, Nutr Rep Intl 28, 899-911, 1983.
9. Figge HL, Figge J, Souney PF et al. Nicotinic acid. A review of its clinical use in the treatment of lipid disorders. Pharmacotherapy 8: 287-294, 1988.
10. Gaby SK. Vitamin intake and health: A scientific review. New York: Marcel Dekker. p 189-192, 1991.
11. Goldsmith GA, Miller ON, Unglaub WG. Efficiency of tryptophan as a niacin precursor in man. J Nutr 73: 172-176, 1961.
12. Grundy SM. Drug therapy in dyslipidemia. Scand J Clin Lab Invest 50: 63-72, 1990.
13. Illingworth DR et al., Comparative Effects of Lovastatin and Niacin in Primary Hypercholesterolemia, Arch Intern Med 154, 1586-95, 1994.
14. Jacob, RA, Swendseid, ME. Niacin. In: Present knowledge in nutrition. 7th edn. Washington DC: International Life Sciences Press. p 184-190, 1996.
15. Jonas WB et al. The effect of niacinamide on osteoarthritis: a pilot study. Inflamm Res 45: 330-4, 1996.
16. Lefavi R. Lipid-lowering effects of a dietary nicotinic acid-chromium III complex in male athletes. FASEB J 5;6:A1645, 1991.
17. Lefavi R et al. Lipid-lowering effect of a dietary chromium III-nicotinic acid complex in male athletes. Nutr Res 13:239-49, 1993.
18. Luria MH. Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high density lipoprotein cholesterol ratio. Arch Intern Med 148: 2493-5, 1988.
19. Mandrup Paulsen T. Nicitinamide in the Prevention of Insulin Dependent Diabetes Mellitus. Diabetes Metabol Rev 9: 295-309, 1993.
20. McKenney JM et al., A Comparison of the Efficacy and Toxic Effects of Sustained- vs Immediate-Release Niacin in Hypercholesterolemic Patients, JAMA 271, 672-7, 1994.
21. O’Hara J, Jolly PN, Nicol CG. The therapeutic efficacy of inositol nicotinate (I lexopal) in intermittent claudication of a controlled trial. Br J Clin Practice 42: 377-383, 1988.
22. Patterson JI, Brown RR, Lindswiler H et al. Exertion of tryptophan-niacin metabolites by young men. Effects of tryptophan, leucine, and vitamin B6 intakes. Am J Clin Nutr 33: 2157-2167, 1980.
23. Pocoit F, Reimers JI and Andersen HU. Nicotinamide: Biological Actions and Therapeutic Potential in Diabetes Prevention. Diabetologia 36: 574-76, 1993.
24. Pozzilli P et al. The Potential Role of Nicotinamide in the Secondary Prevention of IDDM. Diabetes Metabol Rev 9: 219-30, 1993.
25. Salem and Abdel M. The Role of Nicotinic Acid and Inositol Hexaniacinate as Anticholesterolemic and Antilipemic Agents. Nutr Rep Intl 28: 899-911, 1983.
26. Urberg M and Zemel MB. Evidence for Synergism Between Chromium and Nicotinic Acid in the Control of Glucose Tolerance in Elderly Humans. Metabolism 36: 896-99, 1987.
27. Urberg M et al. Hypocholesterolemic effect of nicotinic acid and chromium supplementation. J Fam Pract 27;6:603-6, 1988.
28. Vega GL and Crundy SM. Lipoprotein Responses to Treatment with Lovastatin, Gemfibrozil, and Nicotinic Acid in Normolipidemic Patients with Hypoalphalipoproteinemia, Arch Intern Med 154: 73-82, 1994.
29. Welsh AL and Ede M, Inositol Hexanicotinate for Improved Nicotinic Acid Therapy, Int Record Med 174: 9-15, 1961.

 

Sources
Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.